Cortellis Deals Intelligence

Cortellis Deals Intelligence
Product Description

Benefit from the industry's highest quality and largest deals database.
Effective deal making is crucial for company growth, getting drugs/devices to market and overall commercial success. Cortellis Deals Intelligence™ provides the essential data foundation to quickly find the most optimal deal without compromising due diligence, combining:


  • The largest and highest quality deals database
  • Custom analytics based on your specific search criteria
  • Insights on true deal structures
  • Enhanced visualizations for fast evaluation and comparison

Clarivate

  • US
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Academic/Research
Consultancy
IT/Software solution provider
Primary activities
Analytical Services
Technology

Clarivate

  • US
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Academic/Research
Consultancy
IT/Software solution provider
Primary activities
Analytical Services
Technology

More Products from Clarivate (4)

  • Cortellis CMC Intelligence

    Product Cortellis CMC Intelligence

    Cortellis CMC Intelligence product is a comprehensive database of guidelines / granular collection of CMC data requirements for initial registration of small-molecule and biologics drugs around the world that can be used to avoid delays in product approval and successfully bring a drug to the market (launc...
  • Cortellis Competitive Intelligence

    Product Cortellis Competitive Intelligence

    Gaining a competitive edge in drug development requires monitoring the current pipeline while keeping an eye to the future. Cortellis Competitive Intelligence™ delivers timely intelligence to survey the entire development landscape and provides comprehensive analysis to forecast trends, threats and opportu...
  • Cortellis Drug Discovery Intelligence

    Product Cortellis Drug Discovery Intelligence

    Biology, chemistry and pharmacology data –all in one place.
    Accelerate drug development with early, comprehensive intelligence. Collating the necessary data to identify the likelihood of a drug’s success as early as possible requires considerable resources. Cortellis Drug Discovery Intelli...
  • Cortellis Generics Intelligence

    Product Cortellis Generics Intelligence

    Never miss an opportunity using the most comprehensive intelligence available. Success in the highly competitive generics market requires speed and data-driven decisions to grow your business, defend your market share, stay ahead of competition and identify new markets, products and partners. Have confiden...

Clarivate resources (3)

  • News API market tested by COVID-19 but pandemic is accelerating adoption of supply chain solutions: CPHI panel

    CPHI Discover panel of industry experts discusses impact of COVID-19 on API manufacturing and trading as well as the controversial topic of reshoring production
  • Video The API Landscape - Reshoring, Trading & Sourcing Dynamics

    This webinar originally aired as part of CPHI Discover - 17-28 May 2021 THIS IS A LIVE STREAM SESSION - After broadcast it will be available to view on-demand for the remainder of the event. API manufacturing has always been about innovating to cater for shifting demand patterns, but the recent coronavirus pandemic has raised further questions about manufacturing hubs and consistency of supply. Are we on the brink of a major shift in API production? The complexity of globally interconnected pharmaceutical supply chains Market pressures to modernize API supply chains through digitization The advantage of increased real-time visibility in its supply chain The role of trading in the API supply chain Offshore vs Onshore Manufacturing Could reshoring represent an opportunity for boosting innovation and new manufacturing technologies to compete effectively and take a greener approach? This session will feature a live Q&A where you can put your questions to our expert panel.
  • Webinar Biosimilars in Oncology

    The availability of of biologic therapies to treat oncology disease conditions has led to improved clinical outcomes, but the high cost can create barriers and disparities in treatment access, and therefore outcomes. The use of biosimilars can improve patients' access to care by decreasing treatment costs and creating price competition between the originator product and biosimilar competitors. Watch this Clarivate webinar on-demand now to understand the following: What is the current landscape of biosimilars in oncology? How do biosimilar approvals and market access differ between the United States and Europe? What is interchangeability and what is its impact? What are the barriers to uptake of biosimilars in oncology? What is the future of biosimilars in oncology?